HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 1 (2004), Issue 3 (October)

1. HIV-1 infection among injection and ex-injection drug users from Rio de Janeiro, Brazil: prevalence, estimated incidence and genetic diversity.
   J Clin Virol, 31(3): 221-6. [Abstract] [Full-text]
2. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
   J Clin Virol, 31(3): 215-20. [Abstract] [Full-text]
3. Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies.
   J Clin Virol, 31(3): 190-7. [Abstract] [Full-text]
4. Inhibition of HIV-1 infection in cells expressing an artificial complementary peptide.
   Biochem Biophys Res Commun, 324(1): 236-40. [Abstract] [Full-text]
5. Endosomal membrane traffic: convergence point targeted by Mycobacterium tuberculosis and HIV.
   Cell Microbiol, 6(11): 999-1009. [Abstract] [Full-text]
6. Viruses adsorbed on musculoskeletal allografts are inactivated by terminal ethylene oxide disinfection.
   J Orthop Res, 22(6): 1358-61. [Abstract] [Full-text]
7. Use of antipsychotic medications among HIV-infected individuals with schizophrenia.
   Schizophr Res, 71(2): 435-44. [Abstract] [Full-text]
8. Zinc coupling potentiates anti-HIV-1 activity of baicalin.
   Biochem Biophys Res Commun, 324(2): 605-10. [Abstract] [Full-text]
9. Does tuberculosis increase HIV load?
   J Infect Dis, 190(9): 1677-84. [Abstract] [Full-text]
10. Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain.
    Virology, 329(1): 180-8. [Abstract] [Full-text]
11. Multiple residues in the extracellular domains of CCR3 are critical for coreceptor activity.
    Virology, 329(1): 109-18. [Abstract] [Full-text]
12. Molecular clock-like evolution of human immunodeficiency virus type 1.
    Virology, 329(1): 101-8. [Abstract] [Full-text]
13. Cell cycle regulation of human immunodeficiency virus type 1 integration in T cells: antagonistic effects of nuclear envelope breakdown and chromatin condensation.
    Virology, 329(1): 77-88. [Abstract] [Full-text]
14. EBV positive primary cutaneous CD30+ large T-cell lymphoma in a heart transplanted patient: case report.
    Am J Transplant, 4(11): 1915-20. [Abstract] [Full-text]
15. Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection.
    J Virol, 78(21): 12066-70. [Abstract] [Full-text]
16. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1.
    J Virol, 78(21): 12062-5. [Abstract] [Full-text]
17. APOBEC3G incorporation into human immunodeficiency virus type 1 particles.
    J Virol, 78(21): 12058-61. [Abstract] [Full-text]
18. The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity.
    J Virol, 78(21): 12054-7. [Abstract] [Full-text]
19. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.
    J Virol, 78(21): 12030-40. [Abstract] [Full-text]
20. Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4.
    J Virol, 78(21): 12022-9. [Abstract] [Full-text]
21. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.
    J Virol, 78(21): 12012-21. [Abstract] [Full-text]
22. Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies.
    J Virol, 78(21): 11980-7. [Abstract] [Full-text]
23. Interaction between the cytoplasmic domain of ICAM-1 and Pr55Gag leads to acquisition of host ICAM-1 by human immunodeficiency virus type 1.
    J Virol, 78(21): 11916-25. [Abstract] [Full-text]
24. Endocytic host cell machinery plays a dominant role in intracellular trafficking of incoming human immunodeficiency virus type 1 in human placental trophoblasts.
    J Virol, 78(21): 11904-15. [Abstract] [Full-text]
25. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
    J Virol, 78(21): 11841-52. [Abstract] [Full-text]
26. Influence of gag on human immunodeficiency virus type 1 species-specific tropism.
    J Virol, 78(21): 11816-22. [Abstract] [Full-text]
27. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype.
    J Virol, 78(21): 11807-15. [Abstract] [Full-text]
28. Between-host evolution of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1: an approach based on phylogenetically independent comparisons.
    J Virol, 78(21): 11758-65. [Abstract] [Full-text]
29. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA.
    J Virol, 78(21): 11739-50. [Abstract] [Full-text]
30. Differential effects on human immunodeficiency virus type 1 replication by alpha-defensins with comparable bactericidal activities.
    J Virol, 78(21): 11622-31. [Abstract] [Full-text]
31. Impact on genetic networks in human macrophages by a CCR5 strain of human immunodeficiency virus type 1.
    J Virol, 78(21): 11477-86. [Abstract] [Full-text]
32. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
    J Epidemiol Community Health, 58(11): 944-50. [Abstract] [Full-text]
33. Vpx proteins of SIVmac239 and HIV-2ROD interact with the cytoskeletal protein alpha-actinin 1.
    J Gen Virol, 85: 3291-303. [Abstract] [Full-text]
34. Kaposi's varicelliform eruption in an HIV-positive patient after laser resurfacing.
    J Eur Acad Dermatol Venereol, 18(6): 711-2. [Abstract] [Full-text]
35. Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation.
    Mol Cell Biol, 24(21): 9286-94. [Abstract] [Full-text]
36. Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model.
    Trans R Soc Trop Med Hyg, 98(12): 695-701. [Abstract] [Full-text]
37. Recall antigen activation induces prompt release of CCR5 ligands from PBMC: implication in memory responses and immunization.
    Int Immunol, 16(11): 1623-31. [Abstract] [Full-text]
38. IL-10 production induced by HIV-1 Tat stimulation of human monocytes is dependent on the activation of PKC beta(II) and delta isozymes.
    Microbes Infect, 6(13): 1182-90. [Abstract] [Full-text]
39. Complement-opsonized HIV: the free rider on its way to infection.
    Mol Immunol, 42(2): 153-60. [Abstract] [Full-text]
40. Mannose binding lectin (MBL) and HIV.
    Mol Immunol, 42(2): 145-52. [Abstract] [Full-text]
41. A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men.
    Drug Alcohol Depend, 76(2): 203-12. [Abstract] [Full-text]
42. A parametric survival model with an interval-censored covariate.
    Stat Med, 23(20): 3159-75. [Abstract] [Full-text]
43. Conserved residues in the HIV-1 Nef hydrophobic pocket are essential for recruitment and activation of the Hck tyrosine kinase.
    J Mol Biol, 343(5): 1255-68. [Abstract] [Full-text]
44. Effects of mutations in an HIV-1 gag gene containing a 107-codon tandem repeat in the matrix region on assembly and processing of the protein product.
    J Med Virol, 74(4): 528-35. [Abstract] [Full-text]
45. Taskforce 8: ethics of medically assisted fertility treatment for HIV positive men and women.
    Hum Reprod, 19(11): 2454-6. [Abstract] [Full-text]
46. Report of the results of a 2 year programme of sperm wash and ICSI treatment for human immunodeficiency virus and hepatitis C virus serodiscordant couples.
    Hum Reprod, 19(11): 2581-6. [Abstract] [Full-text]
47. Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection.
    J Infect Dis, 190(10): 1889-92. [Abstract] [Full-text]
48. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission.
    J Infect Dis, 190(10): 1880-8. [Abstract] [Full-text]
49. Design, synthesis and biological evaluation of novel non-nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties.
    Bioorg Med Chem, 12(22): 5865-73. [Abstract] [Full-text]
50. Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo.
    Antiviral Res, 64(2): 93-102. [Abstract] [Full-text]
51. Expression of Werner and Bloom syndrome genes is differentially regulated by in vitro HIV-1 infection of peripheral blood mononuclear cells.
    Clin Exp Immunol, 138(2): 251-8. [Abstract] [Full-text]
52. Anti-AIDS agents. Part 62: anti-HIV activity of 2'-substituted 4-methyl-3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (4-methyl DCK) analogs.
    Bioorg Med Chem Lett, 14(23): 5855-7. [Abstract] [Full-text]
53. 3-O-Glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents.
    Bioorg Med Chem Lett, 14(23): 5851-3. [Abstract] [Full-text]
54. Acute promyelocytic leukemia and HIV-1 infection: case report and review of the literature.
    Am J Hematol, 77(3): 287-90. [Abstract] [Full-text]
55. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
    Antimicrob Agents Chemother, 48(11): 4387-94. [Abstract] [Full-text]
56. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
    Antimicrob Agents Chemother, 48(11): 4349-59. [Abstract] [Full-text]
57. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.
    Antimicrob Agents Chemother, 48(11): 4189-94. [Abstract] [Full-text]
58. Vpr and Vpu are important for efficient human immunodeficiency virus type 1 replication and CD4+ T-cell depletion in human lymphoid tissue ex vivo.
    J Virol, 78(22): 12689-93. [Abstract] [Full-text]
59. Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels.
    J Virol, 78(22): 12638-46. [Abstract] [Full-text]
60. Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope.
    J Virol, 78(22): 12625-37. [Abstract] [Full-text]
61. Murine T cells potently restrict human immunodeficiency virus infection.
    J Virol, 78(22): 12537-47. [Abstract] [Full-text]
62. Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001.
    J Virol, 78(22): 12455-61. [Abstract] [Full-text]
63. Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3.
    J Virol, 78(22): 12438-45. [Abstract] [Full-text]
64. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.
    J Virol, 78(22): 12428-37. [Abstract] [Full-text]
65. Expression of human immunodeficiency virus type 1 gag modulates ligand-induced downregulation of EGF receptor.
    J Virol, 78(22): 12386-94. [Abstract] [Full-text]
66. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.
    J Virol, 78(22): 12344-54. [Abstract] [Full-text]
67. CXCR4-dependent infection of CD8+, but not CD4+, lymphocytes by a primary human immunodeficiency virus type 1 isolate.
    J Virol, 78(22): 12288-96. [Abstract] [Full-text]
68. Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter.
    J Virol, 78(22): 12198-206. [Abstract] [Full-text]
69. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function.
    Cell, 119(3): 381-92. [Abstract] [Full-text]
70. Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5.
    Gene Ther, 11(22): 1627-37. [Abstract] [Full-text]
71. Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase.
    J Neurosci, 24(43): 9531-40. [Abstract] [Full-text]
72. Contagious apoptosis facilitated by the HIV-1 envelope: fusion-induced cell-to-cell transmission of a lethal signal.
    J Cell Sci, 117: 5643-53. [Abstract] [Full-text]
73. Viral load of human herpesvirus 8 (HHV-8) in the circulatory blood cells correlates with clinical progression in a patient with HHV-8-associated solid lymphoma with aids-associated Kaposi's sarcoma.
    Leuk Lymphoma, 45(11): 2343-7. [Abstract] [Full-text]
74. Cell cycle distribution of CD4+ lymphocytes in HIV-1-infected subjects.
    Cytometry B Clin Cytom, 62(1): 46-51. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.